

## Media Release

Zug, 17 February 2014

### **HBM Healthcare Investments participates with EUR 20 million in financing round of Advanced Accelerator Applications**

Advanced Accelerator Applications (“AAA”, “the Company”), a privately held company domiciled in Saint-Genis-Pouilly, France, today announced the closing of a financing round of EUR 41 million. HBM Healthcare Investments led the financing with an investment of EUR 20 million. Dr. Andreas Wicki will be proposed to join the Company’s Board.

AAA is a fast growing international specialist in Molecular Nuclear Medicine that develops and commercializes innovative diagnostic and therapeutic products. Its main focus is on molecular imaging and targeted therapy for the treatment of diseases such as cancer. AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) products, with 17 production and R&D facilities in Europe, Israel and North America.

The Company has been profitable since 2006 with the sales of its diagnostic products and has used this positive cash flow to finance its growing portfolio of Molecular Nuclear Medicine products, including Lu-DOTATATE (Lutathera<sup>®</sup>), which is currently in phase III clinical trials for the treatment of Gastro-Entero-Pancreatic Neuro Endocrine Tumours (an Orphan disease) in 51 clinical centers in the US and EU. Lutathera<sup>®</sup> is a true example of a Theragnostic drug, because it integrates diagnostic and therapeutic properties into the same compound, allowing physicians to evaluate and monitor its efficacy using imaging at every therapeutic injection, without any additional costs.

The funds of the financing will be used to accelerate the Company’s international expansion, including an increased presence in the US and to finance the clinical development of its promising portfolio of innovative Molecular Nuclear Medicine.

Dr. Andreas Wicki, Chief Executive Officer of HBM Healthcare Investments comments: *“We believe that AAA’s approach to targeted therapy is very interesting and will further advance product development and innovation in Molecular Nuclear Medicine, a niche which has been poorly exploited until now. AAA as one of the market leaders in this field in Europe and with its profile as*

# NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

## HBM Healthcare Investments

*an innovative, fast growing and profitable company with a promising late-stage development pipeline is a valuable addition to our portfolio and a prime example for our investment strategy in private equity. Together with the HBM team I will be happy to support the Company on its way to further success.”*

For further information, please contact Dr. Andreas Wicki, tel.: +41 41 768 11 08, [andreas.wicki@hbmhealthcare.com](mailto:andreas.wicki@hbmhealthcare.com)

### About Advanced Accelerator Applications

Advanced Accelerator Applications (AAA) is a European pharmaceutical company founded in 2002 to develop innovative diagnostic and therapeutic products. AAA's main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine). AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 270 employees in 10 countries (France, Italy, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S., Canada). In 2013 AAA is expecting to reach revenues of €56.6 million (+27% vs. 2012) and EBITDA of €14 million (+49% vs. 2012). For more information please visit: [www.adacap.com](http://www.adacap.com)

### About Molecular Nuclear Medicine (MNM)

Molecular Nuclear Medicine is a medical specialty using trace amounts of active substances, called radiopharmaceuticals, to create images of organs and lesions and to treat various diseases, like cancer. The technique works by injecting into the patient's body targeted radiopharmaceuticals that accumulate in the organs or lesions that reveal specific biochemical processes.

Molecular Nuclear Diagnostics employs a variety of imaging devices and radiopharmaceuticals. PET (Positron Emission Tomography) and SPECT (Single Photon Emission Tomography) are highly sensitive imaging technologies that enable physicians to diagnose different types of cancer, cardiovascular diseases, neurological disorders and other diseases in their early stages.

Theranostics is today used to define “companion drugs”. This means that a therapeutic drug is developed and is approved to be used together with a diagnostic test. The test can tell you if the drug is suitable for a specific disease in a specific patient and checks if the treatment could be effective, thus increasing the cost-effectiveness of the whole treatment. MNM gives the perfect meaning to the word “theragnostics” because it can integrate diagnostics and therapeutics properties into the same single drug and it is a key discipline in the transition from population-based to personalized medicine.

#### HBM Healthcare Investments Ltd

# NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

## HBM Healthcare Investments

### Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of some twenty five promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

### Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

### HBM Healthcare Investments Ltd

Bundesplatz 1 | CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | [info@hbmhealthcare.com](mailto:info@hbmhealthcare.com)  
[www.hbmhealthcare.com](http://www.hbmhealthcare.com)